BioCanRx, Canada’s Immunotherapy Network, is a network of scientists, clinicians, cancer stakeholders, academic institutions, NGOs and industry partners working together to accelerate the development of leading edge immune oncology therapies for the benefit of patients. BioCanRx is becoming a world-leader in the translation, manufacture and adoption of cancer immunotherapies. Through an innovative, collaborative research funding process, BioCanRx invests in translating Canadian technologies from the lab into early phase clinical trials, and addresses socio-economic considerations necessary for their adoption by health-care systems. The network is committed to training and developing the talent needed for a thriving health biotechnology sector in Canada. BioCanRx receives funding from the federal government’s Networks of Centres of Excellence, and support from industry, the provinces and charities.
BioCanRx is a Network of Centres of Excellence.
The Networks of Centres of Excellence program is funded by Canada’s federal government. For more information about the NCE program visit: http://www.nce-rce.gc.ca/Index_eng.asp
To view the NCE’s BioCanRx network page, click here: http://www.nce-rce.gc.ca/NetworksCentres-CentresReseaux/NCE-RCE/BioCanRx_eng.asp